- Home
- AXGN vs TSHA Comparison
AXGN vs TSHA Comparison
Compare AXGN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXGN | TSHA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AXGN | TSHA |
|---|---|---|
| Price | $31.59 | $4.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $33.67 | $10.56 |
| AVG Volume (30 Days) | 770.0K | ★ 3.3M |
| Earning Date | 02-24-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $214,709,000.00 | $6,310,000.00 |
| Revenue This Year | $21.60 | N/A |
| Revenue Next Year | $15.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $9.22 | $1.05 |
| 52 Week High | $34.71 | $6.02 |
Technical Indicators
Market Signals| Indicator | AXGN | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 41.71 |
| Support Level | $30.32 | $4.80 |
| Resistance Level | $34.71 | $5.69 |
| Average True Range (ATR) | 1.50 | 0.31 |
| MACD | -0.27 | -0.13 |
| Stochastic Oscillator | 29.42 | 16.44 |
Price Performance
Historical ComparisonAbout AXGN Axogen Inc.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.